P05.097 Hypoglycaemic Treatment And Chronic Renal Disease In Diabetic Patients

Conference: 
Author(s): 
A. Pedro Pijoan, V. Grahit Vidosa, S. P‚rez Zamora, F. Flor, A. Vericat Roure, C. Ram¡rez Sanchez;
Consorci Sanitari Integral- Gaud¡ Salut, Barcelona, Spain.
Anna Maria Pedro Pijoan
Consorci Sanitari Integral- Gaud¡ Salut
Barcelona
Zip: 08025
Spain
Email: annamariapj@yahoo.es
Phone: 0034610628312
Text: 
AIM
There are different recommendations known with hypoglycaemic treatment in diabetic patients with chronic kidney disease (CKD).
It is known that sulphonylurea glipizide is recommended in patients with chronic kidney disease (CKD). Hypoglycaemia remains a risk with glipizide.
This study is aimed to determine the prevalence of diabetes type 2 patients treated with sulphonylurea and CKD registered. Secondary objective is to describe hypoglycaemic treatments in diabetics patients with CKD.
DESIGN & METHODS
Cross-sectional study of a random sample of diabetic patients with filled renal stage by blood test assigned and visited in our Primary Care Centre during 2010.
Inclusion criteria: Subjects >over 15 years with diabetes and CKD (glomerular filtration rate (GFR) Exclusion criteria: terminal diseases, pregnancy, not having results of analytics and exitus.
Following variables are considered: age, sex, body mass index (BMI), CKD diagnosis, diabetes diagnosis, hypoglycaemic treatments, diagnosis of HTA and dyslipidaemia. Evaluation indicators were calculated following International Guidelines.
RESULTS
16770 visited patients, where 1396 have diabetes, and 189 with CKD diagnosis. 50% were women and mean age was 79,5 (8,7). Mean BMI?30=32,2%, 90,3% had been diagnosed of hypertension and 53,5% of dyslipidaemia. Only 144 patients were studied with GFR between 30-60= 83,3%; between 15-29=16%; From 144 patients, 110 (76,4%) have hypoglycaemic treatment and 34 (23,6%) without.
Results pending.
CONCLUSIONS
In this study we attempted to identify those diabetic patients treated with sulphonylurea that perhaps could benefit from alternative therapies with the aim to preserve renal function. We have observed a low prevalence of CKD.
We expect that our diabetic patients should have to be more controlled as they have a high risk in diabetic complications. But we should be aware about our prescriptions for the security of our patients.
Literature: 
P05.097
Hypoglycaemic treatment and Chronic renal disease in diabetic patients